HDAC and MAPK/ERK Inhibitors Cooperate To Reduce Viability and Stemness in Medulloblastoma-Reference-Cited by-同舟云学术

HDAC and MAPK/ERK Inhibitors Cooperate To Reduce Viability and Stemness in Medulloblastoma

Published:2020-02-13 Issue:6 Volume:70 Page:981-992
ISSN:0895-8696
Container-title:Journal of Molecular Neuroscience
language:en
Short-container-title:J Mol Neurosci

Author:

da Cunha Jaeger Mariane,Ghisleni Eduarda Chiesa,Cardoso Paula Schoproni,Siniglaglia Marialva,Falcon Tiago,Brunetto André T.,Brunetto Algemir L.,de Farias Caroline Brunetto,Taylor Michael D.,Nör Carolina,Ramaswamy Vijay,Roesler Rafael^ORCID

Funder

National Council for Scientific and Technological Development

PRONON/Ministry of Health, Brazil

Rio Grande do Sul State Research Foundation

Coordination for the Improvement of Higher Education Personnel

Clinical Hospital institutional research fund

Programa Nacional de Pós-Doutorado

Brain Tumour Foundation of Canada

Canadian Institutes for Health Research

American Brain Tumor Association

National Institutes of Health

Pediatric Brain Tumour Foundation

Terry Fox Research Institute

Canadian Institutes of Health Research

Cure Search Foundation

b.r.a.i.n.child

Meagan’s Walk

Genome Canada

Genome BC

Ontario Institute for Cancer Research

Canadian Cancer Society Research Institute

Publisher

Springer Science and Business Media LLC

Subject

Cellular and Molecular Neuroscience,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12031-020-01505-y.pdf

Reference62 articles.

1. Annabi B, Rojas-Sutterlin S, Laflamme C, Lachambre MP, Rolland Y, Sartelet H, Béliveau R (2008) Tumor environment dictates medulloblastoma cancer stem cell expression and invasive phenotype. Mol Cancer Res 6:907–916

2. Armstrong L, Hughes O, Yung S, Hyslop L, Stewart R, Wappler I, Peters H, Walter T, Stojkovic P, Evans J, Stojkovic M, Lako M (2006) The role of PI3K/AKT, MAPK/ERK and NF kappa beta signalling in the maintenance of human embryonic stem cell pluripotency and viability highlighted by transcriptional profiling and functional analysis. Hum Mol Genet 15:1894–1913

3. Bonfim-Silva R, Salomão KB, Pimentel TVCA, Menezes CCBO, Palma PVB, Fontes AM (2019) Biological characterization of the UW402, UW473, ONS-76 and DAOY pediatric medulloblastoma cell lines. Cytotechnology 71:893–903

4. Cavalli FMG, Remke M, Rampasek L, Peacock J, Shih DJH, Luu B, Garzia L, Torchia J, Nör C, Morrissy AS, Agnihotri S, Thompson YY, Kuzan-Fischer CM, Farooq H, Isaev K, Daniels C, Cho BK, Kim SK, Wang KC, Lee JY, Grajkowska WA, Perek-Polnik M, Vasiljevic A, Faure-Conter C, Jouvet A, Giannini C, Nageswara Rao AA, Li KKW, Ng HK, Eberhart CG, Pollack IF, Hamilton RL, Gillespie GY, Olson JM, Leary S, Weiss WA, Lach B, Chambless LB, Thompson RC, Cooper MK, Vibhakar R, Hauser P, van Veelen MC, Kros JM, French PJ, Ra YS, Kumabe T, López-Aguilar E, Zitterbart K, Sterba J, Finocchiaro G, Massimino M, Van Meir EG, Osuka S, Shofuda T, Klekner A, Zollo M, Leonard JR, Rubin JB, Jabado N, Albrecht S, Mora J, Van Meter TE, Jung S, Moore AS, Hallahan AR, Chan JA, Tirapelli DPC, Carlotti CG, Fouladi M, Pimentel J, Faria CC, Saad AG, Massimi L, Liau LM, Wheeler H, Nakamura H, Elbabaa SK, Perezpeña-Diazconti M, Chico Ponce de León F, Robinson S, Zapotocky M, Lassaletta A, Huang A, Hawkins CE, Tabori U, Bouffet E, Bartels U, Dirks PB, Rutka JT, Bader GD, Reimand J, Goldenberg A, Ramaswamy V, Taylor MD (2017) Intertumoral heterogeneity within medulloblastoma subgroups. Cancer Cell 31:737–754

5. Chang CJ, Chiang CH, Song WS, Tsai SK, Woung LC, Chang CH, Jeng SY, Tsai CY, Hsu CC, Lee HF, Huang CS, Yung MC, Liu JH, Lu KH (2012) Inhibition of phosphorylated STAT3 by cucurbitacin I enhances chemoradiosensitivity in medulloblastoma-derived cancer stem cells. Childs Nerv Syst 28:363–373

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CircRNA and lncRNA-associated competing endogenous RNA networks in medulloblastoma: a scoping review;Cancer Cell International;2024-07-15

2. Overcoming Treatment Resistance in Medulloblastoma: Underlying Mechanisms and Potential Strategies;Cancers;2024-06-18

3. Re-expression of epigenetically silenced PTPRR by histone acetylation sensitizes RAS-mutant lung adenocarcinoma to SHP2 inhibition;Cellular and Molecular Life Sciences;2024-01-28

4. Current and future therapeutic strategies for high-grade gliomas leveraging the interplay between epigenetic regulators and kinase signaling networks;Journal of Experimental & Clinical Cancer Research;2024-01-05

5. Differential Signaling Pathways in Medulloblastoma: Nano-biomedicine Targeting Non-coding Epigenetics to Improve Current and Future Therapeutics;Current Pharmaceutical Design;2024-01